0.75
price down icon0.17%   -0.0013
after-market アフターアワーズ: .76 0.01 +1.33%
loading
前日終値:
$0.7513
開ける:
$0.75
24時間の取引高:
251.63K
Relative Volume:
0.23
時価総額:
$1.60M
収益:
$4.70M
当期純損益:
$-4.99M
株価収益率:
-0.1168
EPS:
-6.42
ネットキャッシュフロー:
$-5.29M
1週間 パフォーマンス:
+21.99%
1か月 パフォーマンス:
-29.25%
6か月 パフォーマンス:
-70.93%
1年 パフォーマンス:
-78.57%
1日の値動き範囲:
Value
$0.7117
$0.78
1週間の範囲:
Value
$0.62
$0.78
52週間の値動き範囲:
Value
$0.4519
$7.20

Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile

Name
名前
Salarius Pharmaceuticals Inc
Name
セクター
Healthcare (1164)
Name
電話
346-772-0346
Name
住所
2450 HOLCOMBE BLVD, HOUSTON
Name
職員
2
Name
Twitter
@SalariusPharma
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
SLRX's Discussions on Twitter

SLRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SLRX
Salarius Pharmaceuticals Inc
0.75 1.60M 4.70M -4.99M -5.29M -6.42
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2020-04-27 開始されました Ladenburg Thalmann Buy

Salarius Pharmaceuticals Inc (SLRX) 最新ニュース

pulisher
Jul 25, 2025

What analysts say about Salarius Pharmaceuticals Inc. stockExceptional earning trajectories - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Is Salarius Pharmaceuticals Inc. a good long term investmentRapid market gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 22, 2025

What drives Salarius Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Salarius Pharmaceuticals Inc. Stock Analysis and ForecastRobust financial gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Salarius Pharmaceuticals Modifies Security Holders’ Rights - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange - Investing.com Australia

Jul 21, 2025
pulisher
Jul 16, 2025

Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% – What’s Next? - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

How Salarius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Return Analysis - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Salarius Pharmaceuticals Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Salarius Pharmaceuticals Inc. stock price move sharplyShort Squeeze Radar - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Salarius Pharmaceuticals Granted Nasdaq Compliance Extension - The Globe and Mail

Jul 15, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance - MSN

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals Granted Extension to Regain Compliance With Nasdaq's Stockholders' Equity Requirement - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy Therapeutics - Quiver Quantitative

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard - The Manila Times

Jul 14, 2025
pulisher
Jul 14, 2025

SLRX gets Nasdaq extension; equity deadline moves to late-July 2025 | NDSN SEC FilingForm 8-K - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals Granted Additional Extension to - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Secures Critical Nasdaq Extension Amid $2.5M Equity Requirement Challenge - Stock Titan

Jul 14, 2025
pulisher
Jul 10, 2025

Salarius Pharmaceuticals’ Seclidemstat Demonstrates - GlobeNewswire

Jul 10, 2025
pulisher
Jul 09, 2025

Salarius Pharmaceuticals, Inc. Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewswire

Jul 09, 2025
pulisher
Jul 09, 2025

Breakthrough Studies Support Salarius Cancer Drug Effectiveness While Clinical Trials Show Promise - Stock Titan

Jul 09, 2025
pulisher
Jul 09, 2025

Salarius Pharmaceuticals reports progress in LSD1 inhibitor study, merger with Decoy Therapeutics. - AInvest

Jul 09, 2025

Salarius Pharmaceuticals Inc (SLRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
大文字化:     |  ボリューム (24 時間):